Melphalan
- Generic Name
- Melphalan
- Brand Names
- Alkeran, Evomela, Phelinun, Pepaxti
- Drug Type
- Small Molecule
- Chemical Formula
- C13H18Cl2N2O2
- CAS Number
- 148-82-3
- Unique Ingredient Identifier
- Q41OR9510P
- Background
Melphalan is a nitrogen mustard or bischloroethylamine type alkylating agent. It was first synthesized in the early 1950s by substituting L-phenylalanine for the methyl group on nitrogen mustard. Melphalan is used in the treatment of multiple myeloma and ovarian carcinoma. It is also used for high-conditioning before hematopoietic stem cell transplant. It is also used to treat uveal melanoma with unresectable hepatic metastases.
- Indication
Melphalan is indicated for use as a high-dose conditioning treatment prior to hematopoietic stem cell transplantation in patients with multiple myeloma. It is also indicated for the palliative treatment of multiple myeloma and for the palliation of non-resectable epithelial carcinoma of the ovary.
Melphalan is a component of HEPZATO KIT, a liver-directed therapy indicated for the treatment of adults with uveal melanoma with unresectable hepatic metastases affecting less than 50% of the liver and no extrahepatic disease or extrahepatic disease limited to the bone, lymph nodes, subcutaneous tissues, or lung that is amenable to resection or radiation.
- Associated Conditions
- Multiple Myeloma (MM), Unresectable Liver Metastasis, Unresectable Ovarian Cancer (Epithelial)
- Associated Therapies
- Conditioning regimens for allogeneic stem cell transplantation therapy
Biparental HLA Haplotype Disparate T-cell Depleted Transplants for Patients Lacking an HLACompatible Donor
- Conditions
- Interventions
- First Posted Date
- 2012-05-15
- Last Posted Date
- 2018-08-09
- Lead Sponsor
- Memorial Sloan Kettering Cancer Center
- Target Recruit Count
- 3
- Registration Number
- NCT01598025
- Locations
- 🇺🇸
Memorial Sloan Kettering Cancer Center, New York, New York, United States
Safety and Efficacy Study of High Dose Melphalan to Treat Multiple Myeloma
- First Posted Date
- 2012-04-06
- Last Posted Date
- 2012-08-02
- Lead Sponsor
- Shandong Lanjin Pharmaceuticals Co.,Ltd
- Target Recruit Count
- 60
- Registration Number
- NCT01572688
- Locations
- 🇨🇳
Hematologic Hospital of Chinese Academy of Medical Sciences, Tianjin, China
Tandem Auto Transplantation in Myeloma Patients With <12 Months of Prior Treatment
- First Posted Date
- 2012-03-08
- Last Posted Date
- 2017-06-14
- Lead Sponsor
- University of Iowa
- Target Recruit Count
- 19
- Registration Number
- NCT01548573
- Locations
- 🇺🇸
University of Iowa Holden Comprehensive Cancer Center, Iowa City, Iowa, United States
Y Zevalin and BEAM in Autologous Stem Cell Transplantation (ASCT) for Lymphoma
- Conditions
- Interventions
- First Posted Date
- 2012-02-24
- Last Posted Date
- 2014-09-11
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 40
- Registration Number
- NCT01538472
- Locations
- 🇺🇸
UT MD Anderson Cancer Center, Houston, Texas, United States
Isolated Limb Infusion Chemotherapy With Targeted Gene Therapy for Advanced, Unresectable Extremity Melanoma
- Conditions
- Interventions
- First Posted Date
- 2012-02-10
- Last Posted Date
- 2014-07-18
- Lead Sponsor
- Washington University School of Medicine
- Registration Number
- NCT01531244
Fludarabine Phosphate, Melphalan, and Low-Dose Total-Body Irradiation Followed by Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Hematologic Malignancies
- Conditions
- Accelerated Phase Chronic Myelogenous LeukemiaAdult Acute Myeloid Leukemia in RemissionChildhood Acute Myeloid Leukemia in RemissionChildhood Chronic Myelogenous LeukemiaChildhood Grade III Lymphomatoid GranulomatosisAdult Acute Lymphoblastic Leukemia in RemissionAdult Acute Myeloid Leukemia With 11q23 (MLL) AbnormalitiesAdult Acute Myeloid Leukemia With Del(5q)Adult Acute Myeloid Leukemia With Inv(16)(p13;q22)Adult Acute Myeloid Leukemia With t(8;21)(q22;q22)
- Interventions
- First Posted Date
- 2012-02-09
- Last Posted Date
- 2019-09-24
- Lead Sponsor
- Roswell Park Cancer Institute
- Target Recruit Count
- 94
- Registration Number
- NCT01529827
- Locations
- 🇺🇸
Roswell Park Cancer Institute, Buffalo, New York, United States
High Dose Chemotherapy and Autologous Transplant for Neuroblastoma
- First Posted Date
- 2012-02-06
- Last Posted Date
- 2024-02-26
- Lead Sponsor
- Masonic Cancer Center, University of Minnesota
- Target Recruit Count
- 13
- Registration Number
- NCT01526603
- Locations
- 🇺🇸
Masonic Cancer Center, University of Minnesota, Minneapolis, Minnesota, United States
Stem Cell Transplantation for Patients With Multiple Myeloma
- Conditions
- Interventions
- First Posted Date
- 2012-02-03
- Last Posted Date
- 2024-01-29
- Lead Sponsor
- University of Chicago
- Target Recruit Count
- 15
- Registration Number
- NCT01526096
- Locations
- 🇺🇸
University of Chicago, Chicago, Illinois, United States
Planned Donor Lymphocyte Infusion (DLI) After Allogeneic Stem Cell Transplantation (SCT)
- First Posted Date
- 2012-01-25
- Last Posted Date
- 2016-03-17
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 16
- Registration Number
- NCT01518153
- Locations
- 🇺🇸
University of Texas MD Anderson Cancer Center, Houston, Texas, United States
Auto Transplant for High Risk or Relapsed Solid or CNS Tumors
- Conditions
- Interventions
- First Posted Date
- 2012-01-06
- Last Posted Date
- 2024-02-26
- Lead Sponsor
- Masonic Cancer Center, University of Minnesota
- Target Recruit Count
- 44
- Registration Number
- NCT01505569
- Locations
- 🇺🇸
Masonic Cancer Center, University of Minnesota, Minneapolis, Minnesota, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.